Predictive value of c-erbB-2 and Cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis

Clinical Cancer Research

Volumn 5, Issue 4, 1999, Pages 815-821

  Scorilas, Andreas ^a   Yotis, Julia ^a   Pateras, Charilaos ^a   Trangas, Theoni ^a   Talieri, Maroulio ^a,b  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; ONCOPROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CATHEPSIN D; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GREECE; HUMANS; LOGISTIC MODELS; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; SURVIVAL RATE;

EID: 0032907690     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Downward, J., Yarden, Y., Mayes, T., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., and Waterfield, M. D. Close similarity of epidermal growth factor receptor and v-erbB oncogene protein sequences. Nature (Lond.), 307: 521-527, 1984.
2. Schechter, A. L., Hung, M. C., Vaidyanathan, L., Weinberg, R. A., Yaugfeng, T. L., Francke, U., Ullrich, A., and Coussens, L. The neu gene: an erbB homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science (Washington DC), 229: 976-978, 1985.
3. Bargmann, C. L., Hung, M. C., and Weinberg, R. A. The neu oncogene encodes an epidermal growth factor receptor related protein. Nature (Lond.), 319: 226-230, 1986.
4. van de Vijver, M., Peferse, J. L., Mooi, W. J., Wisman, P., Lomans, J., Dalesio, O., and Nusse, R. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognosis value in stage II breast cancer. N. Engl. J. Med., 319: 1239-1245, 1988.
5. Berger, M. S., Locher, G. W., Saurer, S., Gullick, W. J., Waterfield, M. D., Grower, B., and Hynes, N. E. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res., 48: 1238-1243, 1988.
6. Borg, A., Tandon, A. K., Sigurdsson, H., Clark, G. M., Fernö, M., Fuqua, S. A. W., Killander, D., and McGuire, W. L. Her-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res., 50: 4332-4337, 1990.
7. Tsuda, H., Hirohashi, S., Shimosato, Y., Hirota, T., Tsugane, S., Yamamoto, H., Miyajima, N., Toyoshima, K., Yamamoto, T., Yokota, J., Yoshida, T., Sakamoto, H., Terada, M., and Sugimura, T. Correlation two putative oncogene- amplification units: hst-1/int-2 and c-erbB-2/ ear-1. Cancer Res., 49: 3104-3108, 1989.
8. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the Her2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
9. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
10. O'Malley, F. P., Saad, Z., Kerkvliet, N., Doig, G., Stitt, L., Ainsworth, P., Hundal, H., Chambers, A. F., Turnbull, D. I., and Bramwell. V. The predictive power of semiquantitative immunohistochemical assessment of pS3 and c-erbB-2 in lymph node-negative breast cancer. Hum. Pathol., 27: 955-963, 1996.
11. Lonn, U., Lonn, S., Nilsson, B., and Stenkvist, B. Prognostic significance of c-erbB-2 amplification in fine-needle biopsies of breast cancer patients not operated at diagnosis. Breast Cancer Res. Treat., 39: 213-220, 1996.
12. Verbeek, A., Adriaansen-Slot, S. S., Vroom, T. M., and Rijksen, G. Overexpression of EGFR and c-erbB-2 causes enhanced cell migration in human breast cells and NIH3T3 fibroblasts. FEBS Lett, 425: 145-150, 1998.
13. Rochefort, H. Biological and clinical significance of cathepsin-D in breast cancer. Acta Oncol., 31: 125-130, 1992.
14. Rochefort, H., Capony, F., Garcia, M., Cavilles, V., Freiss, G., Chambon, M., Morrisset, M., and Vignon, F. Estrogen-induced lysosomal proteases secreted by breast cancer cells: a role in carcinogenesis? J. Cell. Biochem., 35: 17-29, 1987.
15. Spyratos, F., Maudelonde, T., Brouillet, J. P., Brunet, M., DeFenne, A., Andrieu, C., Hacene, K., Desplaces, A., Rouesse, J., and Rochefort, H. Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet, 2: 1115-1118, 1989.
16. Duffy, M. J., Reilly, D., Brouillet, J. P., McDermott, E. N. M., Faul, C., O'Higgins, N., Fennelly, J. J., Maudelonde, T., and Rochefort, H. Cathepsin D concentration in breast cancer cytosols: correlation with disease-free interval and overall survival. Clin. Chem., 38: 2114-2116, 1992.
17. Maudelonde, T., Daures, J. P., Rouanet, P., Brouillet, J. P., Pujol, H., and Rochefort, H. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer (Phila.), 71: 2006-2012, 1993.
18. Ardavanis, A., Scorilas, A., Amanatidou, A., Gerakini, F., Missitzis, I., Garoufali, A., Pissakas, G., Pateras, C., Apostolikas, N., Rigatos, G., Yotis, I. Cathepsin-D concentration in tumor cytosols improves the accuracy of prognostic evaluation of primary breast cancer. Anticancer Res., 17: 1405-1409, 1997.
19. Garcia, M., Plutet, N., Liaudet, E., Laurent, V., Derocq, D., Brouillet, J. P., and Rochefort, H. Biological and clinical significance of cathepsin-D in breast cancer metastasis. Stem Cells, 14: 642-650, 1996.
20. Jarvinen, T., Holli, K., Kuukasjarvi, T., and Isola, J. Predictive value of topoisomerase II a and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br. J. Cancer, 77: 2267-2273, 1998.
21. Sjogren, S., Inganas, M., Lindgren, A., Holmberg, L., and Bergh, J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J. Clin. Oncol., 16: 462-469, 1998.
22. Scorilas, A., Yotis, J., Gouriotis, D., Keramopoulos, A., Ampela, K., Trangas, T., and Talieri, M. Cathepsin-D, and c-erbB-2 have an additive prognostic value for breast cancer patients. Anticancer Res., 13: 1895-1900, 1993.
23. Scorilas, A., Yotis, J., Stravolemos, K., Gouriotis, D., Keramopoulos, A., Ampela, K., Talieri, M., and Trangas, T. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients. Anticancer Res., 15: 1543-1548, 1995.
24. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
25. Davis, L. G., Dibuer, M. D., and Battey, J. F. Basic Methods in Molecular Biology. New York: Elsevier 1980.
26. Feinberg, A. P., and Vogelstein, B. A technique for labeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem., 132: 8-13, 1983.
27. Thomas, P. S. Hybridization of denatured RNA and small DNA fragments transferred to a high specific activity. Proc. Natl. Acad. Sci. USA, 77: 5201-5205, 1980.
28. Maniatis, T., Fritsch, E. F., and Sambrock, J. Molecular Cloning. A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1982.
29. Miyada, C. G., and Wallace, R. B. Oligonucleotide hybridization techniques. Methods Enzymol., 154: 94-107, 1987.
30. Kute, T. E., Hushe, M. S., and Phyme, A. C. Improvements in steroid receptor assays including rapid computer analysis of data. Anal. Biochem., 103: 272-279, 1980.
31. EORTC Breast Cancer Cooperative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur. J. Cancer, 16: 1513-1515, 1980.
32. Tormod, B., and Egil, A. Selecting risk factors: a comparison of discriminant analysis logistic regression and Cox's regression model using data from the tromso heart study. Stat. Med., 4: 413-423, 1985.
33. Westley, B., and Rochefort, H. A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell, 20: 353-362, 1980.
34. Rochefort, H., Liaudet, E., and Garcia, M. Alterations and role of human cathepsin-D in cancer metastasis. Protein, 49: 106-116, 1996.
35. Ardavanis, A., Gerakini, F., Amanatidou, A., Scorilas, A., Pateras, C., Garoufali, A., Pissakas, G., Stravolemos, K., Apostolikas, N., and Yotis, I. Relationships between cathepsin-D, pS2 protein and hormonal receptors in breast cancer cytosols: inconsistency with their established prognostic significance. Anticancer Res., 77: 3665-3670, 1997.
36. Ravdin, P. M., Tandon, A. K., Allred, D., Clark, G., Fugua, S., Hilsenbeck, S., Chamnes, G., and Osborne, C. Cathepsin-D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J. Clin. Oncol., 12: 467-474, 1994.
37. Ardavanis, A., Scorilas, A., Loukeri, A., Gerakini, F., Pissakas, G., Missitzis, I., Apostolikas, N., and Yiotis I. Cathepsin D may help in discriminating node-negative breast cancer patients at risk for local-regional recurrence. Anticancer Res., 18: 2885-2890, 1998.
38. Kandalaft, P., Chang, K., Ahn, C., Traneek, S., Mehta, P., and Battifora, H. Prognostic significance of immunohistochemical analysis of cathepsin D in low-stage breast cancer. Cancer (Phila.), 71: 2756-2763, 1993.
39. Losch, A., Tempfer, C., Kohlberger, P., Joura, E. A., Denk, M., Zajic, B., Breitenecker, G., and Kainz, C. Prognostic value of cathepsin D expression and association with histomorphological subtypes in breast cancer. Br. J. Cancer, 78: 205-209, 1998.
40. Ferrandina, G., Scambia, G., Bardelli, F., Benedetti-Panici, P., Mancuso, S., and Messori, A. Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br. J. Cancer, 76: 661-666, 1997.
41. Johnson, M. D., Torri, J. A., and Lippman, M. E. The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res., 52: 6101-6105, 1992.
42. Têfu, B., Brisson, J., Côte, C., Brisson, S., Potvin, D., and Roberge, N. Prognostic significance of cathepsin-D expression in node positive breast carcinoma: an immunohistochemical study. Int. J. Cancer, 55: 429-435, 1993.
43. Razumovic, J. J., Stojkovic, R. R., Petrovecki, M., and Gamulin, S. Correlation of two methods for determination of cathepsin-D in breast carcinoma (immunohistochemical and ELISA in cytosol). Breast Cancer Res. Treat., 43: 117-122, 1997.
44. Spyratos, F., Martin, P. M., Hacene, K., Romain, S., Andrieu, C., Ferrero-Rous, M., Deytieux, S., Le Doussal, U., Tabiana-Hulin, M., and Brunet, M. Multiparametric prognostic evaluation of biological factors in primary breast cancer. J. Natl. Cancer Inst, 84: 1266-1272, 1992.
45. Ravdin, P. M, de-Moor, CA., Hilsenbeck, S. G., Samoszuk, M. K., Vendely, P. M., and Clark, G. M. Lack of prognostic value of cathepsin-D levels for predicting short term outcomes of breast cancer patients. Cancer Lett., 116: 177-183, 1997.
46. Berns, E., Klijn, J., van Putten, W., van Staveren, I., Portengen, H., and Foekens, J. c-myc amplification is a better prognostic factor than Her2/neu amplification in primary breast cancer. Cancer Res., 52: 1107-1113, 1992.
47. Kreipe, H., Feist, H., Fischer, L., Feigner, J., Heidory, K., Mettler L., and Parwatesch, R. Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Res., 53: 1956-1961, 1993.
48. Valeron, P. F., Chirino, R., Vega, V., Falcon, O., Rivero, J. F., Torres, S., Leon, L., Fernandez, L., Pestano, J., Diaz-Chico, B., and Diaz-Chico, J. C. Quantitative analysis of P185 (HER-2/neu) protein in breast cancer and its association with other prognostic factors. Int J. Cancer, 74: 175-179, 1997.
49. Anan, K., Morisaki, T., Katano, M., Ikubo, A., Tsukahara, Y., Kojima, M., Uchigma, A., Kuroki, S., Torisu, M., and Tanaka, M. Assessment of c-erbB-2 and vascular endothelial growth factor mRNA expression in fine-meddle aspirates from early breast carcinoma: preoperative determination of malignant potential. Eur. J. Surg. Oncol., 24: 28-33, 1998.
50. Beckmann, M. W., Niederacher, D., Massenkeil, G., Tutsckek, B., Beckmann, A., Schenku, G., Schnurch, H. G., and Bender, H. G. Expression analyses of epidermal growth factor receptor and HER-2/ neu: no advantage of prediction of recurrence or survival in breast cancer patients. Oncology, 53: 441-447, 1996.
51. Koscielny, S., Terrier, P., Daver, A., Wafflart, J., Goussard, J., Ricolleau, G., Delvincourt, C., and Delarue, J. C. Quantitative determination of c-erbB-2 in human breast tumors: potential prognostic significance of low values. Eur. J. Cancer, 34: 476-481, 1998.
52. Charpin, C., Garcia, S., Bouvier, C., Martini, F., Lavaut, M-N., Allasia, C., Bonnier, P., and Andrac, L. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival. Br. J. Cancer, 75: 1667-1673, 1997.
53. Allred, D. C., Harvey, J. M., Berardo, M., and Clark, G. M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol., 11: 155-168, 1998.